EFM
E Fund Management’s Recursion Pharmaceuticals RXRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $201K | Sell |
39,653
-16,272
| -29% | -$82.3K | 0.01% | 362 |
|
|
2025
Q1 | $296K | Buy |
55,925
+13,604
| +32% | +$72K | 0.01% | 317 |
|
|
2024
Q4 | $286K | Sell |
42,321
-1,097
| -3% | -$7.42K | 0.01% | 324 |
|
|
2024
Q3 | $286K | Buy |
43,418
+19,253
| +80% | +$127K | 0.01% | 266 |
|
|
2024
Q2 | $181K | Sell |
24,165
-14,562
| -38% | -$109K | 0.01% | 296 |
|
|
2024
Q1 | $386K | Sell |
38,727
-15,367
| -28% | -$153K | 0.02% | 229 |
|
|
2023
Q4 | $533K | Sell |
54,094
-2,638
| -5% | -$26K | 0.03% | 149 |
|
|
2023
Q3 | $434K | Buy |
56,732
+39,503
| +229% | +$302K | 0.03% | 148 |
|
|
2023
Q2 | $129K | Sell |
17,229
-4,188
| -20% | -$31.4K | 0.01% | 293 |
|
|
2023
Q1 | $143K | Sell |
21,417
-5,694
| -21% | -$38K | 0.01% | 313 |
|
|
2022
Q4 | $209K | Buy |
27,111
+15,252
| +129% | +$118K | 0.02% | 297 |
|
|
2022
Q3 | $126K | Buy |
+11,859
| New | +$126K | 0.01% | 323 |
|